

SOLRIAMFETOL tablets (Sunosi® ▼) for treating excessive daytime sleepiness caused by obstructive sleep apnoea

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of SOLIRAMFETOL tablets (Sunosi® ▼), for treating excessive daytime sleepiness caused by obstructive sleep apnoea in accordance with NICE TA777.

BLACK

[NICE technology appraisal \(TA\) 777](#) does not recommend solriamfetol, within its marketing authorisation, to improve wakefulness and reduce excessive daytime sleepiness in adults with obstructive sleep apnoea (OSA) whose sleepiness has not been satisfactorily treated by primary obstructive sleep apnoea therapy, such as continuous positive airway pressure (CPAP).¹

NICE states that excessive daytime sleepiness caused by OSA is usually first treated with a primary OSA therapy such as CPAP (standard care). Clinical trial evidence shows that solriamfetol alone and when added to standard care reduces excessive daytime sleepiness compared with standard care alone, however the trial evidence does not show an improvement in quality of life. This may be because of how it was measured in the trials. It is likely that reducing excessive daytime sleepiness translates into improved quality of life, but it is uncertain by how much. There are also concerns about how the trial data has been used in the economic model. Therefore, the cost-effectiveness estimates for solriamfetol compared with standard care alone are uncertain. They are also likely to be higher than what NICE normally considers an acceptable use of NHS resources. So, solriamfetol is not recommended by NICE for treating excessive daytime sleepiness caused by OSA.¹

Clinicians should continue to follow local pathways for the treatment of OSA.

Solriamfetol is also licensed for treating excessive daytime sleepiness in adults with narcolepsy with or without cataplexy. Pan Mersey APC supports use for this indication only in strict accordance with NICE TA 758 and the Pan Mersey APC prescribing statement [SOLRIAMFETOL tablets \(Sunosi® ▼\) for treating excessive daytime sleepiness caused by narcolepsy](#).

References

1. National Institute for Health and Care Excellence. Technology appraisal 777; [Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea](#), 09 March 2022. Accessed 10 March 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.